Washington—About 85% of a cohort of Alaskans who received the hepatitis B vaccine at age 6 months or older showed evidence of protection after 35 years, although some may require a booster dose, according to a study presented at the 2017 Liver Meeting.
“No chronic hepatitis B infections were identified in the cohort,” according to lead study author Michael Bruce, MD, MPH, an epidemiology team leader in the CDC’s Arctic Investigation Program Division